Indian Journal of Dermatology
CORRESPONDENCE
Year
: 2011  |  Volume : 56  |  Issue : 4  |  Page : 444-

Omalizumab in treatment-resistant chronic spontaneous urticaria


Kiran V Godse 
 Skin Department, Shree Skin Centre, 22, L market, Sector 8, Nerul, Navi Mumbai, India

Correspondence Address:
Kiran V Godse
Skin Department, Shree Skin Centre, 22, L market, Sector 8, Nerul, Navi Mumbai
India




How to cite this article:
Godse KV. Omalizumab in treatment-resistant chronic spontaneous urticaria.Indian J Dermatol 2011;56:444-444


How to cite this URL:
Godse KV. Omalizumab in treatment-resistant chronic spontaneous urticaria. Indian J Dermatol [serial online] 2011 [cited 2021 Dec 4 ];56:444-444
Available from: https://www.e-ijd.org/text.asp?2011/56/4/444/84737


Full Text

Sir,

According to EAACI/GA 2 LEN/EDF/WAO guidelines, chronic spontaneous urticaria (CSU) is defined by the spontaneous occurrence of wheals and/or angioedema over more than 6 weeks. [1] GA 2 LEN task force report mentions that the detrimental effect of CSU on the quality of life is greater than that of most other skin diseases and similar to that of severe coronary artery disease. [2] Guideline mentions omalizumab as the fourth-line option in the treatment of CSU. [3] First-line options are non-sedating antihistamines in fourfold doses, and second-line options include leukotriene antagonist or changing non-sedating antihistamine. There are few reports of success of omalizumab in the treatment of CSU. [4],[5] Omalizumab, a recombinant, humanized, monoclonal antibody against immunoglobulin IgE, represents a unique therapeutic approach for the treatment of allergic diseases.

We treated five patients with treatment-resistant CSU with omalizumab. Dose of omalizumab was calculated according to body weight and serum IgE level. All patients had severe urticaria that required multiple antihistamines, steroids or dapsone to control symptoms. In spite of therapy, they had severe symptoms like urticaria, angioedema and itching. Patients were treated with omalizumab according to the dose schedule of asthma [Table 1]. Treatment study period was 4 months. Treatment response was assessed by urticaria activity score (UAS) and need of antihistamines or other therapies. The UAS was recorded by each patient daily and was obtained from the patients weekly. The number of wheals was scored from 0 to 3: 0, no wheals; 1, less than 20 wheals; 2, 20-50 wheals; 3, >50 wheals almost covered large confluent areas of wheals. Severity of itch was scored as 0, none; 1, mild; 2, moderate; and 3, severe. One has to add both these scores, viz., for both the number of wheals and the severity of itch, on a given day for each of the days in a given week to get the weekly UAS. The possible weekly aggregate UAS thereby ranged from 0 to 42. Daily average score ranged between 0 and 6.{Table 1}

There was significant improvement in all the patients, with reduction in UAS and need of antihistamines. At the end of 4 th month, two patients were free from symptoms and other three required antihistamine to control their symptoms. Side effects were recorded in two patients in the form of headache and fatigue.

Study from Germany reported that all nine patients who had severe therapy-resistant urticaria improved with omalizumab. [6] Physical urticaria patients have also shown overall excellent response to omalizumab in the study from Germany. [7]

This paper supports latest EAACI/GA 2 LEN/WAO/EDF guideline which mentions the use of omalizumab as a fourth-line treatment in CSU.

References

1Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gime´nez-Arnau A et al. EAACI/ GA 2 LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64:1417-26.
2Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet P, Bousquet J et al. Unmet clinical needs in chronic spontaneous urticaria. A GA 2 LEN task force report(1). Allergy 2011;66:317-30.
3Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gime´nez-Arnau A et al. EAACI/ GA 2 LEN/EDF/WAO guideline: Management of urticaria. Allergy 2009;64:1427-43.
4Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122:569-73.
5Godse KV. Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol 2008;74:157-8.
6Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P. Omalizumab-An effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011;66:303-5.
7Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011;154:177-80.